Intravenous (IV) therapy is a cornerstone of modern medical care, enabling rapid and controlled delivery of fluids, medications and nutrition. However, consideration must be given to the use of in-line filters to maintain patient safety. This product focus outlines the benefits of using Pall Medical in-line filters, which have emerged as a vital measure to mitigate the risks of inadvertently administering particulate matter, microorganisms, endotoxins, and air bubbles during infusion therapy. The use of Pall Medical in-line filters can enhance patient safety and clinical outcomes, particularly in high-risk settings such as neonatal care, oncology, and intensive care units. The use of these filters is outlined in two clinical case studies here. First, the use of Pall Medical TNA1E and NLF2E 1.2 µm (lipid) filters, which has been shown to adhere to current practice guidelines. The case study discusses the use of 1.2 µm in-line filters for the administration of parenteral nutrition in paediatric care to reduce complications and ensure safe infusion practice. The second case study details the integration of the Pall Medical 0.2 µm Supor AEF low protein binding IV in-line filter for the administration of monoclonal antibodies in an outpatient infusion centre setting. This filter was chosen to standardise clinical practice as it was suitable for all the monoclonal antibody infusions. The need to standardise this practice and maintain safety is discussed.
Barton et al. (Thu,) studied this question.